1 / 16

Design of Small Molecule Drugs Targeted to RNA

Design of Small Molecule Drugs Targeted to RNA. RNA Ontology Group May 29 2007. Small Molecule and Large Molecule Drug Design. “Small Molecule” Drugs Low MW Moderately hydrophobic/hydrophilic Moderately chemical complexity “Biologicals” Peptides/peptidomimetics Engineered enzymes

gwyn
Télécharger la présentation

Design of Small Molecule Drugs Targeted to RNA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May 29 2007

  2. Small Molecule and Large Molecule Drug Design • “Small Molecule” Drugs • Low MW • Moderately hydrophobic/hydrophilic • Moderately chemical complexity • “Biologicals” • Peptides/peptidomimetics • Engineered enzymes • Antisense/RNAi • Need help to enter cells!

  3. “New Tools” for Drug Discovery (1980s and 90s) • Combinatorial Chemistry Increased the number of available compounds • High Throughput Screening (“HTS”) Increases throughput for testing (robotics, databasing) “It’s a Numbers Game”

  4. Rational Drug Design = the Opposite of “It’s a Numbers Game” Protein Structure Design small molecule to “fit” and block active site Voila! Doesn’t work! In Silico High Throughput Docking: A rational numbers game

  5. Membrane Permeability & “Drug-Likeness” • The Lipinski “Rule of Five”

  6. Fragment Library Design • Fragments must be “lead-like” not “drug-like” • MW < 250, allows compound to “grow” • Weak binding affinity (will add affinity with growth) • Contain polar groups • Insures solubility • Polar groups are reactive • Pick up hydrogen bonding interactions • N fragments can cover the chemical space of N2 compounds

  7. Lipinski Rule of 5 • Molecular Weight < 500 Daltons • cLogP < 5 • < 10 Acceptor Groups (O+N) • < 5 Donor Groups ( O-H, N-H) • Exceptions work by active transport Thiostrepton MW 1665 Paromomycin MW 616 Erythromycin MW 734 Tetracycline MW 444

  8. Examples of Small Molecule Molders/Regulators of RNA Secondary Structure in Bacteria SAH No effect SAM Kd=20-200 nM 2,6 diaminopurine Kd=10 nM Purine Kd=100 µM

  9. Examples of Small Molecule Molders/Regulators of RNA Secondary Structure in Bacteria Riboflavin Kd=3 µM FMN Kd=5 nM L-Lysine Kd=1 µM D-Lysine No effect

  10. Lipinski RNA-binding Protein-binding b a c druggable

  11. Current Databases • Pdb title search: RNA gets 2173 hits: “ternary” • Structure description search for ribonucleic acid: 6 hits (2 DNA) • NDB search for RNA + ligand: 841 hits, including protein/RNA complex • Most ligand databases oriented to search for proteins/ligands

  12. Database of RNA Binding Compounds • Antibiotics • Riboswitch ligands • Drug discovery programs (published) • Published findings of natural products • 105 compounds in all

  13. Database of RNA Binding Compounds (caveats) • Only 25 compounds had pdb coordinates • Reported Kd < 50 μM • Redundancy: does not include near neighbors • pdb coordinates did not identify non-contacting substructures

  14. Database of RNA Binding Compounds (further needs) • DNA binding compounds • Classification • Correlation with RNA motifs/pharmacophores

  15. HTS Paradigm X SeeDs Paradigm (Structural Exploration of Exploitable Drug Startpoints) • X-ray/NMR • Chemistry • SBDD Grow potent, selective ligands from fragment • Drug lead-like fragments • No steric inhibition of scaffolds • ~ mM binding Fragment based approaches • >500k compounds screened • assays usually require mM hits • Template decoration often prevents interaction • Need to reduce MW of weak binders prior • to modification HTS requires “right” compounds in library

More Related